Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Verastem Inc 117 KENDRICK STREET SUITE 500 NEEDHAM MA 02494 USA

www.verastem.com P: 781-292-4200

Description:

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

Key Statistics

Overview:

Market Capitalization, $K 275,857
Enterprise Value, $K 259,197
Shares Outstanding, K 25,308
Annual Sales, $ 0 K
Annual Net Income, $ -87,370 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -27,890 K
EBIT, $ -92,080 K
EBITDA, $ -93,330 K
60-Month Beta 0.58
% of Insider Shareholders 2.20%
% of Institutional Shareholders 88.37%
Float, K 24,751
% Float 97.80%
Short Volume Ratio 0.51

Growth:

1-Year Return 106.44%
3-Year Return -68.13%
5-Year Return -33.21%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 75.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.02 on 03/14/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -4.10
EPS Growth vs. Prev Qtr -36.00%
EPS Growth vs. Prev Year -6.21%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 06/01/23

VSTM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -127.00%
Return-on-Assets % -54.73%
Profit Margin % 0.00%
Debt/Equity 0.51
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 4.57
Book Value/Share 3.10
Interest Coverage -20.10
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar